Cambridge, UK, 17 December 2018: Horizon Discovery Group plc (AIM: HZD), a global leader in the application of gene editing and gene modulation technologies, today announces that it has entered into an exclusive target discovery partnership with C4X Discovery Holdings plc (AIM: C4XD) ("C4XD"), a pioneering drug discovery company. The partnership aims to validate the novel synthetic lethal oncology targets that Horizon has identified using its cutting-edge CRISPR-Cas9 technology, with C4XD then using its proprietary 4D shape-based chemistry technology (Conformetrix) to discover pre-clinical…
Wetherby and Cambridge, UK, 11 June 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce the appointment of Dr Eliot Forster as Non-Executive Chairman to the Board with immediate effect. Dr Trevor Nichols, who has acted as Chairman of the Board since January 2014, will remain on the Board as a Non-Executive Director.
Dr Forster brings over 25 years of experience in the pharmaceutical and biotechnology industry, most recently leading Immunocore as Chief Executive Officer to become a world-leading immuno-oncology biotech,…
Click below to read:
When health care meets tech: Panelists offer advice for building blended syndicates
Cambridge, UK and Seoul, South Korea, 10 December 2018: Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, and LG Chem Life Sciences, the life sciences division of the South Korean LG Group, today announced a multi-target collaboration and development agreement. The agreement provides LG Chem with the exclusive rights to develop and commercialize, on a worldwide basis, multiple Affimer® therapeutics intended for treatment of patients in the fields of inflammatory disorders, and oncology. Under the terms of the agreement, Avacta will generate and carry out…
AMSBIO has expanded its range of Wingless/Integrated (Wnt) recombinant proteins, stable reporter cell lines, antibodies and ELISA kits to assist researchers in the fields of developmental biology and oncology.The Wnt family of cysteine-rich secreted polypeptides comprise more than 16 mammalian family members involved in several important cell functions such as cell cell-cell communication, proliferation, migration, polarity, survival and self-renewal. In addition, the Wnt3a signal plays an important role in the ability of organoids to expand. Additionally, loss of activation of Wnt…
Cambridge, UK, December 11th 2018: PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, today announced CE IVD (European Conformity In-Vitro Diagnostic Medical Devices) certification for its prognostic biomarker test for IBD, PredictSURE IBD™ - the first validated biomarker based prognostic test in inflammatory disease.
Achievement of the CE mark enables PredictImmune to take the test to market across the UK and Europe and also enables development of market access to the rest of the world.
The CE…
Cambridge, UK, 11 December 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced its Founder and Chief Executive Officer, John McCafferty was invited to attend the Nobel Prize Award Ceremony in recognition of his pivotal contribution to the development of antibody phage display technology. The event, held in Stockholm, Sweden on 10th December, celebrated the 2018 Nobel Laureates and the success of phage display technology in modern drug discovery and development, which the Royal Swedish Academy of Sciences recognised in this year’s…
Sandwich, Kent, UK, December 10th 2018 - Discovery Park - and some of the businesses driving its success - will use one of the UK’s leading science events to showcase why it remains the perfect location for science companies looking to grow and collaborate. It will be attending Genesis 2018 with several of its life sciences tenants, showcasing their activities and discussing its plans for the future development of the Park.
Discovery Park is a thriving part of South East England’s life science community with high quality laboratory, office and manufacturing space, access to local…
PRINCETON, NJ – Dec. 5, 2018 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access, today announced the launch of its BaseCase Toolkits, an add-on to BaseCase Interactive which helps pharmaceutical and medical device field representatives better manage and utilize their resources for use during customer presentations. BaseCase Toolkits allows interactive tools – such as mobile apps – to be bundled together with other assets – such as product safety and efficacy data, and marketing assets – into user-friendly, highly-…
AMSBIO introduces ALiCE® - a new high yield cell-free protein expression system.
Cell-free protein expression (CFPE) is today used by protein chemists to quickly produce small amounts of proteins when screening DNA libraries. However current technologies are limited and there is a need for higher protein expression yields.
ALiCE® is a unique eukaryotic system, which yields an unprecedented 3 mg/ml of protein in batch mode. Even prokaryotic systems, which generally can only handle easy-to-express proteins, only get at their best 1 mg/ml protein in batch mode.
These higher…